论文部分内容阅读
目的:探讨普伐他汀联合阿司匹林治疗急性脑梗死的临床疗效和预后。方法:115例急性脑梗死患者,随机分为普伐他汀联合阿司匹林治疗组(57例)和单用阿司匹林治疗组(58例),随访6个月,比较两组治疗前、后的美国国立卫生研究院卒中量表(NIHSS)评分、日常生活能力指数(BI)、改良的Rankin(mRS)评分和简易智能量表(MMSE)评分。结果:两组患者在治疗后3和6个月的NIHSS、BI和mRS评分均比治疗前有好转,差异均有统计学意义(P<0.05)。普伐他汀联合阿司匹林治疗组在治疗后6个月时NIHSS、BI和mRS评分的好转优于单用阿司匹林治疗组,且差异均有统计学意义(P<0.05)。MMSE的变化无统计学意义。结论:普伐他汀联合阿司匹林治疗有利于神经功能、日常生活能力的恢复,改善预后,可作为急性脑梗死治疗的联合药物。
Objective: To investigate the clinical efficacy and prognosis of pravastatin combined with aspirin in the treatment of acute cerebral infarction. Methods: One hundred and fifteen patients with acute cerebral infarction were randomly divided into pravastatin combined aspirin group (n = 57) and aspirin group (n = 58), followed up for 6 months. Before and after treatment, the American National Health National Institutes of Health Stroke Scale (NIHSS) score, daily living ability index (BI), modified Rankin (mRS) score, and simple intelligence score (MMSE) score. Results: The scores of NIHSS, BI and mRS in both groups were better than those before treatment at 3 and 6 months after treatment, the differences were statistically significant (P <0.05). The improvement of NIHSS, BI and mRS scores in pravastatin and aspirin group was better than that in aspirin group only at 6 months after treatment (P <0.05). MMSE changes were not statistically significant. Conclusions: Pravastatin combined with aspirin is beneficial to the recovery of nerve function, daily living ability and prognosis, and can be used as a combination therapy for acute cerebral infarction.